New MRI techniques to check tumor response in pancreatic cancer
Official title: Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas
Run by Central Hospital, Nancy, France · NCT06842303 · Data updated 2026-11-12
This tests whether adding high-resolution diffusion MRI and magnetic resonance elastography (MRE) can better show tumor response in adults with non-metastatic pancreatic adenocarcinoma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Vandœuvre-lès-Nancy, France) |
| Status | Recruiting |
| Started | June 6, 2025 |
| Main results expected | June 6, 2027 |
| Study ends | June 6, 2027 |
| Registry record updated | July 17, 2025 |
| Trial ID | NCT06842303 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with CT-confirmed non-metastatic pancreatic adenocarcinoma who can have MRI, are able to consent, and meet local social security requirements are eligible.
✕Probably not a fit
Patients with any contraindication to MRI, metastatic disease, inability to consent, pregnancy, minors, or those under certain legal restrictions are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with CT-diagnosed non-metastatic pancreatic adenocarcinoma will undergo MRI exams that include high-resolution diffusion sequences and magnetic resonance elastography. Images from these new sequences will be collected alongside routine imaging and clinical follow-up. Radiologic metrics from the advanced MRI sequences will be compared with standard imaging findings and patient outcomes to see if they provide clearer signs of tumor change. The protocol is performed at a single tertiary center and requires participants to be able to undergo MRI and provide informed consent.
Why it matters
Potential benefit: If successful, the techniques could help doctors see tumor changes more clearly or earlier, which may improve treatment decisions for patients.
How similar studies have gone: Prior pilot work with high-resolution diffusion MRI and MRE has shown promising signals in pancreatic tumors, but these approaches remain exploratory and not yet standard of care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * CT scan diagnosis of non-metastatic pancreatic cancer on contrast-enhanced thoraco-abdomino-pelvic CT; * Adult patient: age ≥ 18 years; * Patient affiliated with a social security system or beneficiary of such a system; * Patient who has received complete information about the research organization and has signed an informed consent form. Exclusion Criteria: * Patient with a contraindication to MRI. * Person referred to in Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code. * Pregnant woman, parturient, or breastfeeding mother; * Minor (non-emancipated) individual; * Adult individual under legal protection (guardianship, curatorship, or judicial safeguard); * Adult individual unable to express consent. * Person deprived of liberty by a judicial or administrative decision, or person undergoing psychiatric care pursuant to Articles L. 32-12-1 and L. 3213-1 of the French Public Health Code.
Where it's running
-
CHRU Nancy
Vandœuvre-lès-Nancy, France, France Recruiting
Study contacts
- Study coordinator: Guillaume DROUOT, PhD
- Email: g.drouot@chru-nancy.fr
- Phone: 0385157666
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.